Stay updated with breaking news from Grant Pickering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include...
08.05.2023 - - Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 - - Full Six-Month Safety Data from Both ...
VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.
Operator: Good afternoon. My name is Lisa, and I will be your conference operator today.
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2... | February 21, 2023